Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KN046 combined with axitinib in advanced non-small cell lung cancer
CTR20221466Phase 2Completed
- Sponsor
- Kanion Pharmaceutical
- Start
- Aug 2022
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab, axitinib in non-small cell lung cancer (NSCLC), sponsored by Kanion Pharmaceutical. Started Aug 2022; status: completed.
02
Drugs
erfonrilimabaxitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221466.